{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T23:38:54Z","timestamp":1792539534615,"version":"4.5.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jemermed.2017.11.031","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T19:30:29Z","timestamp":1518204629000},"page":"522-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety"],"prefix":"10.1016","volume":"54","author":[{"given":"Leslie S.","family":"Zun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2017.11.031_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project BETA psychopharmacology workgroup","volume":"13","author":"Wilson","year":"2012","journal-title":"West J Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/15622975.2015.1132007","article-title":"Assessment and management of agitation in psychiatry: expert consensus","volume":"17","author":"Garriga","year":"2016","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fpsyt.2013.00026","article-title":"Issues in the management of acute agitation: how much current guidelines consider safety?","volume":"4","author":"Pacciardi","year":"2013","journal-title":"Front Psychiatry"},{"issue":"382","key":"10.1016\/j.jemermed.2017.11.031_bib4","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"14","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2017.11.031_bib5","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bcp.12829","article-title":"Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults \u2013 a Swedish nationwide study","volume":"81","author":"Danielsson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib6","doi-asserted-by":"crossref","first-page":"656370","DOI":"10.1155\/2014\/656370","article-title":"Second-generation antipsychotics and extrapyramidal adverse effects","volume":"2014","author":"Divac","year":"2014","journal-title":"BioMed Res Int"},{"issue":"Suppl 2","key":"10.1016\/j.jemermed.2017.11.031_bib7","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.euroneuro.2007.02.004","article-title":"Management of agitation in the acute psychotic patient\u2014efficacy without excessive sedation","volume":"17","author":"Ca\u00f1as","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib8","doi-asserted-by":"crossref","unstructured":"Zun LS. Evidence-based review of pharmacotherapy for acute agitation. Part 1: Onset of efficacy. J Emerg Med. http:\/\/dx.doi.org\/10.1016\/j.jemermed.2017.10.011.","DOI":"10.1016\/j.jemermed.2017.10.011"},{"key":"10.1016\/j.jemermed.2017.11.031_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/JCP.0b013e3181db8715","article-title":"Comparison of intramuscular olanzapine, orally disintegrating olanzapine tablets, oral risperidone solution, and intramuscular haloperidol in the management of acute agitation in an acute care psychiatric ward in Taiwan","volume":"30","author":"Hsu","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib10","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/JCP.0b013e31818aaf6c","article-title":"Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia","volume":"28","author":"Kinon","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.pnpbp.2007.09.007","article-title":"Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation","volume":"32","author":"Villari","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jemermed.2017.11.031_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib14","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/JCP.0000000000000120","article-title":"A double-blind, randomized comparison study of efficacy and safety of intramuscular olanzapine and intramuscular haloperidol in patients with schizophrenia and acute agitated behavior","volume":"34","author":"Chan","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajem.2004.02.021","article-title":"Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia","volume":"22","author":"Kinon","year":"2004","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/JCP.0b013e3182839612","article-title":"Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia","volume":"33","author":"Zhang","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00004714-200108000-00006","article-title":"A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania","volume":"21","author":"Meehan","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/JCP.0b13e318033bd5e","article-title":"Management of acute agitation in patients with bipolar disorder: efficacy and safety of\u00a0intramuscular aripiprazole","volume":"27","author":"Zimbroff","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1192\/bjp.185.1.63","article-title":"Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine","volume":"185","author":"Alexander","year":"2004","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.jcp.0000085406.08426.a8","article-title":"Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation","volume":"23","author":"Baker","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/j.1875-9114.1998.tb03827.x","article-title":"A double-blind study of lorazepam versus the combination of haloperidol and lorazepam in managing agitation","volume":"18","author":"Bieniek","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jemermed.2017.11.031_bib24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4088\/JCP.v65n0315","article-title":"Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam","volume":"65","author":"Currier","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib25","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s002130000658","article-title":"Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial","volume":"155","author":"Daniel","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.jemermed.2017.11.031_bib26","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/ajp.156.1.142","article-title":"Intramuscular flunitrazepam versus intramuscular haloperidol in the emergency treatment of aggressive psychotic behavior","volume":"156","author":"Dorevitch","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4088\/JCP.v62n0104","article-title":"Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients","volume":"62","author":"Lesem","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib28","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/acps.12262","article-title":"A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation","volume":"130","author":"Pratts","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jemermed.2017.11.031_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.4088\/JCP.10m06011yel","article-title":"Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Allen","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib30","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-244X-13-20","article-title":"A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation","volume":"13","author":"Katagiri","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1192\/bjp.bp.110.081513","article-title":"Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine","volume":"198","author":"Lesem","year":"2011","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-5618.2011.00975.x","article-title":"Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine","volume":"14","author":"Kwentus","year":"2012","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.jemermed.2017.11.031_bib33","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study","volume":"15","author":"Battaglia","year":"1997","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annemergmed.2005.07.003","article-title":"Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department","volume":"47","author":"Knott","year":"2006","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib35","first-page":"1167","article-title":"Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam","volume":"12","author":"Martel","year":"2005","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib36","first-page":"744","article-title":"A prospective, double-blind, randomized trial of midazolam versus haloperidol versus lorazepam in the chemical restraint of violent and severely agitated patients","volume":"11","author":"Nobay","year":"2004","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib37","first-page":"298","article-title":"Droperidol vs. haloperidol in the initial management of acutely agitated patients","volume":"45","author":"Resnick","year":"1984","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib38","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/YIC.0000000000000064","article-title":"Efficacy and safety of valproic acid versus haloperidol in patients with acute agitation: results of a randomized, double-blind, parallel-group trial","volume":"30","author":"Asadollahi","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jemermed.2017.11.031_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1590\/S1516-44462011000100008","article-title":"Rapid tranquilization for agitated patients in emergency psychiatric rooms: a randomized trial of olanzapine, ziprasidone, haloperidol plus promethazine, haloperidol plus midazolam and haloperidol alone","volume":"33","author":"Balda\u00e7ara","year":"2011","journal-title":"Rev Bras Psiquiatr"},{"key":"10.1016\/j.jemermed.2017.11.031_bib40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1192\/bjp.bp.114.150227","article-title":"Droperidol v. haloperidol for sedation of aggressive behaviour in acute mental\u00a0health: randomised controlled trial","volume":"206","author":"Calver","year":"2015","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.annemergmed.2016.07.033","article-title":"Midazolam-droperidol, droperidol, or olanzapine for acute agitation: a randomized clinical trial","volume":"69","author":"Taylor","year":"2017","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0196-0644(05)82660-5","article-title":"Droperidol versus haloperidol for chemical restraint of agitated and combative patients","volume":"21","author":"Thomas","year":"1992","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.clinthera.2010.03.006","article-title":"Systematic reviews of assessment measures and pharmacologic treatments for agitation","volume":"32","author":"Zeller","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.jemermed.2017.11.031_bib44","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1016\/j.ajem.2016.09.025","article-title":"Chemical agents for the sedation of agitated patients in the ED: a systematic review","volume":"34","author":"Korczak","year":"2016","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jemermed.2017.11.031_bib45","first-page":"CD003079","article-title":"Benzodiazepines for psychosis-induced aggression or agitation","volume":"9","author":"Gillies","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jemermed.2017.11.031_bib46","first-page":"CD009377","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","volume":"11","author":"Powney","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jemermed.2017.11.031_bib47","first-page":"CD003729","article-title":"Olanzapine IM or velotab for acutely disturbed\/agitated people with suspected serious mental illnesses","volume":"2","author":"Belgamwar","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jemermed.2017.11.031_bib48","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4088\/JCP.v69n1204","article-title":"A\u00a0meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation","volume":"69","author":"Satterthwaite","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eurpsy.2010.04.005","article-title":"OBS-IM investigators group. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania","volume":"27","author":"Perrin","year":"2012","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib50","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jemermed.2017.11.031_bib51","author":"Geodon Summary of Product Characteristics"},{"key":"10.1016\/j.jemermed.2017.11.031_bib52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.5414\/CP202457","article-title":"A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers","volume":"53","author":"Cassella","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.jemermed.2017.11.031_bib53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jcph.257","article-title":"Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT\/QTc study in healthy subjects","volume":"54","author":"Spyker","year":"2014","journal-title":"J Clin Pharmacol"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467917311083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467917311083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:38Z","timestamp":1760027978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467917311083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0736467917311083"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2017.11.031","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-Based Review Of Pharmacotherapy For Acute Agitation. Part 2: Safety","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2017.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}